Join our daily newsletter At The Bell to receive exclusive market insights
- Clarity Pharmaceuticals (CU6) completes recruitment for a phase two trial of its prostate cancer treatment Cu-SAR-Bombesin
- The trial will evaluate the safety of Cu-SAR-Bombesin in 30 patients, looking at the diagnostic potential across two different groups of men
- Clarity Executive Chairman Dr Alan Taylor says the data collected to date is “promising”
- Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death worldwide
- Cu6 shares rose 2.67 per cent trading at 77 cents at 2:40pm AEST
Clarity Pharmaceuticals (CU6) has completed recruitment for a phase two trial of its prostate cancer treatment Cu-SAR-Bombesin.
The investigator-initiated trial will evaluate the safety of Cu-SAR-Bombesin on 30 patients, looking at the diagnostic potential across two different groups of men.
The first group tested have suspected biochemical recurrence of their prostate cancer with negative prostate-specific membrane antigen (PSMA) positron emission tomography imaging scans or low PSMA expression disease.
The second group undergoing the trial are patients with metastatic castrate resistant prostate cancer who are not eligible for PSMA therapy.
“The promising data we are generating on our SAR-Bombesin product has already resulted in the improvements to the management of prostate cancer for patients with PSMA-negative lesions or low PSMA expression in their tumours,” Clarity Executive Chairman Dr Alan Taylor said.
“We hope that the clinical benefits, combined with supply and manufacturing advantages of Targeted Copper Theranostics, will ensure that cancer patients can get their critical treatments on time and at a convenient location, representing a next-generation treatment paradigm focused on the needs of patients and their treating staff.”
Cu-SAR-Bombesin aims to detect prostate cancer in up to 50 PSMAs, providing more treatment options for patients.
Approximately 20 per cent of prostate cancers with a breakpoint cluster region are PSMA-PET negative, and are unlikely to respond to targeted treatment.
The company is focusing its efforts on completing the trial.
Cu6 was up 2.67 per cent trading at 77 cents at 2:40 pm AEST.
